Following the Recommendations of the MediShield Life Council on MediShield Life’s Coverage for Outpatient Cancer Drug Treatments, this list shows the outpatient cancer drugs and clinical indications that are claimable under MediShield Life and MediSave and the corresponding limits. It will be implemented in September 2022.

The subsidy classes in the list applies for drugs at public healthcare institutions, and will be implemented by September 2022 or earlier. Drugs can be subsidised under the Standard Drug List (SDL) or Medication Assistance Fund (MAF). More information on drug subsidies and the full list of subsidised drugs can be found here once the subsidy is implemented.

Frequently Asked Questions (FAQs)

Expand All | Collapse All

Does this list also apply to inpatient cancer drug treatments?

No, inpatient cancer drug treatments are covered separately under the inpatient claim limits, together with other costs incurred during the inpatient stay. For example, the MediShield Life claim limit is $1,000 per day for the first two days and $800 per day for the third and subsequent day of normal ward stay, and the MediSave withdrawal limit is $550 for the first two days and $400 for the third and subsequent day of the ward stay.

What is the criteria for inclusion in this list?

Generally, the outpatient cancer drug list comprises drugs that are clinically proven and cost-effective in treating the particular cancer type. A drug is clinically proven if it is registered with the Health Sciences Authority (HSA) for the particular clinical indication and has met the required standards of safety, quality and efficacy. A drug is cost-effective if it provides good value in treating the particular cancer type compared to existing standard of care, in terms of health benefits and cost.

Who assesses the cost-effectiveness of cancer drug treatments?

The Agency for Care Effectiveness (ACE), Singapore’s national HTA agency, assesses the clinical effectiveness and cost-effectiveness of cancer drug treatments using published methodologies that are in line with international best practices. The MOH Oncology Drug Sub-committee (ODS), comprising local clinical experts from the public and private sectors, will be consulted as part of this process. Negotiations are also conducted to ensure that drug manufacturers have opportunities to offer cost-effective prices.

The MOH Drug Advisory Committee (DAC), chaired by the Director of Medical Services in MOH and comprising senior public sector doctors, pharmacists and MOH representatives, reviews ACE’s evaluations, companies’ price proposals and makes recommendations to MOH for subsidy and MediShield Life coverage. This is similarly done for subsidy recommendations for other drugs and vaccines. For the initial outpatient cancer drug list, reference was taken from the DAC’s subsidy recommendations.

More details on the processes and methods can be found on ACE’s website here.

What happens to cancer drug treatments not on the list?

There will not be MediShield Life coverage for cancer drug treatments that are not on the list. As MediShield Life is a basic national insurance scheme, we need to balance between providing better protection for Singaporeans and keeping premiums affordable. Payouts are ultimately funded through premiums. Targeting MediShield Life coverage at clinically proven and cost-effective cancer drug treatments will enable us to stretch the limited pool of premium dollars and support more patients to receive appropriate treatments.

There will not be MediSave coverage for cancer drug treatments that are not on the list as well. MediSave coverage and contribution rates are generally sized to be sufficient for Singaporeans’ basic healthcare needs, which includes large medical expenses such as hospitalisation episodes, recurring outpatient treatments and premiums for national health insurance schemes, especially in old age. Aligning the scope of MediSave coverage to cancer drug treatments on the list ensures that the limited pool of MediSave monies which Singaporeans have saved up over their working lives are used for clinically proven and cost-effective treatments, and that there remains sufficient balances for other healthcare needs. This will help to keep contribution rates reasonable for all Singaporeans.

We encourage patients to discuss carefully with their doctors about the efficacy of treatments that are not on the list, possible side effects and costs, in order to make an informed decision on whether to proceed with the treatment.

How do I apply for a treatment to be included in the list?

You may wish to discuss this with your doctor to raise such a request.

Oncologists can request ACE to evaluate treatments for potential inclusion on the list if there is sufficient clinical evidence to support their use. For example, rare cancers where the treatment is approved by a reputable overseas regulatory authority but not submitted for HSA's approval due to the small patient pool in Singapore.

Outpatient Cancer Drug List

The subsidy class, and MediShield Life and MediSave limits may change from time to time. The prevailing subsidy class, and MediShield Life and MediSave limits will be applied at the point the patient receives treatment. If more than one cancer drug from the list is used in a month, the patient may claim up to the amounts not exceeding the highest MediShield Life and MediSave claim limits applicable for the individual drugs. For example, if a patient uses both Drugs A (MediShield Life claim limit of $2,000 & MediSave withdrawal limit of $600) and B (MediShield Life claim limit of $1,000 & MediSave withdrawal limit of $600) in a month, the patient may claim no more than $2,000 from MediShield Life and $600 from MediSave in that month.


Click on the column headers to sort. Click Ctrl+F (On Windows) or Cmd+F (On Mac) to look for the specific cancer drug of interest, and check the clinical indication that is covered under MediShield Life and MediSave.
Updated 17 Aug 2021

Active Ingredient(s)Dosage Form(s) and Strength(s)Brand(s)Clinical IndicationSubsidy Class MediShield Life Claim Limit per month ($)MediSave Withdrawal Limit per month ($)
AbemaciclibAbemaciclib tablet (50 mg, 100 mg, 150 mg)VerzenioAbemaciclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer.MAF800600
AbemaciclibAbemaciclib tablet (50 mg, 100 mg, 150 mg)VerzenioAbemaciclib in combination with fulvestrant for treating HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy.MAF800600
AbirateroneAbiraterone tablet (250 mg)-For cancer treatment.SDL (Abiranat)400600
AcalabrutinibAcalabrutinib capsule (100 mg) CalquenceMonotherapy for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy.MAF2000600
AcalabrutinibAcalabrutinib capsule (100 mg) CalquenceAcalabrutinib in combination with obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy. No subsidy2000600
AcalabrutinibAcalabrutinib capsule (100 mg) CalquenceMonotherapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy.MAF2000600
AcalabrutinibAcalabrutinib capsule (100 mg) CalquenceTreatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy.MAF2000600
AfatinibAfatinib tablet (20 mg, 30 mg, 40 mg)GiotrifTreatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer.MAF600600
Aflibercept Aflibercept concentrate for solution for infusion (100 mg/4 mL)ZaltrapAflibercept in combination with FOLFIRI for treating metastatic colorectal cancer that has progressed on first-line systemic therapy.No subsidy(Undergoing Evaluation)(Undergoing Evaluation)
AlectinibAlectinib capsule (150 mg)AlecensaTreatment of locally advanced or metastatic ALK- positive non-small cell lung cancer.No subsidy2000600
AnastrozoleAnastrozole tablet (1 mg)-Treatment of hormone receptor positive, postmenopausal women with early and advanced breast cancer.MAF200600
ApalutamideApalutamide tablet (60 mg) ErleadaTreatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).No subsidy400600
ApalutamideApalutamide tablet (60 mg) ErleadaTreatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC). No subsidy400600
Arsenic trioxideArsenic trioxide injection (10 mg)-For cancer treatment.No subsidy3000600
AtezolizumabAtezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)TecentriqAtezolizumab in combination with nab-paclitaxel for treating patients with unresectable, locally advanced, or metastatic triple negative breast cancer whose tumours have PDL1 expression >1% and who have not received prior chemotherapy for metastatic disease.No subsidy1800600
AtezolizumabAtezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)TecentriqAtezolizumab in combination with a platinum agent and etoposide, for previously untreated extensive-stage small cell lung cancer.No subsidy1800600
AtezolizumabAtezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)TecentriqFor previously untreated metastatic non-small cell lung cancer (NSCLC), in patients whose tumours express PD-L1 with a tumour proportion score ≥50%, with no EGFR or ALK genomic tumour aberrations. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
AtezolizumabAtezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)TecentriqTreatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
AtezolizumabAtezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)TecentriqAtezolizumab in combination with bevacizumab, paclitaxel and carboplatin, for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who had not received prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
AtezolizumabAtezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)TecentriqAtezolizumab in combination with nab-paclitaxel and carboplatin, for previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC), in patients with no EGFR or ALK genomic tumour aberrations. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
AtezolizumabAtezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)TecentriqTreatment of patients with locally advanced or metastatic urothelial carcinoma whose tumours express PD-L1 (PD-L1 stained tumour-infiltrating immune cells [IC] covering ≥5% of the tumour area), and who are not eligible for cisplatin-containing chemotherapy. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
AtezolizumabAtezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)TecentriqTreatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
AtezolizumabAtezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)TecentriqTreatment of patients with locally advanced or metastatic urothelial carcinoma (UC) after receiving platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for UC. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy1800600
AtezolizumabAtezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL)TecentriqAtezolizumab in combination with bevacizumab for treating advanced unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.No subsidy1800600
AvelumabAvelumab concentrate for solution for infusion (200 mg/10 mL)BavencioTreatment of metastatic merkel cell carcinoma.No subsidy1800600
AvelumabAvelumab concentrate for solution for infusion (200 mg/10 mL)BavencioAvelumab in combination with axitinib for untreated advanced renal cell carcinoma. Treatment with PD-1/PD-L1 inhibitor should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
AvelumabAvelumab concentrate for solution for infusion (200 mg/10 mL)BavencioMaintenance treatment of locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-based chemotherapy.No subsidy1800600
AxitinibAxitinib tablet (1 mg, 5 mg)InlytaFor previously treated advanced renal cell carcinoma.No subsidy1600600
AzacitidineAzacitidine injection (100 mg)-For cancer treatment.SDL400600
Bacillus Calmette-Guerin (BCG)Bacillus Calmette-Guerin (BCG) solution for intravesical use (12.5 mg, 40 mg, 80 mg)-For cancer treatment.SDL400600
BendamustineBendamustine injection (25 mg and 100 mg)-For cancer treatment.SDL800600
BevacizumabBevacizumab concentrate for solution for infusion (100 mg/4 mL, 400 mg/16 mL) (Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)
BicalutamideBicalutamide tablet (50 mg, 150 mg)-For cancer treatment.SDL200600
Bleomycin Bleomycin injection (15 USP unit)-For cancer treatment.SDL400600
BlinatumomabBlinatumomab powder for infusion (35 mcg vial)BlincytoTreatment of B-cell precursor acute lymphoblastic leukaemia in first or subsequent complete remission with minimal residual disease (MRD) greater than or equal to 0.1% for: - up to a maximum of one cycle for induction in a lifetime; - and up to three additional cycles for consolidation in a lifetime in patients who are MRD negative. Complete remission is defined as a patient who: a) has 5% or less bone marrow blasts; and b) has no evidence of disease; and c) has a full recovery of peripheral blood counts with platelet count of more than 100,000 per microlitre; and d) absolute neutrophil count of more than 1,000 per microlitreMAF96001200
BlinatumomabBlinatumomab powder for infusion (35 mcg vial)BlincytoTreatment of relapsed or refractory B-precursor acute lymphoblastic leukaemia for: - up to a maximum of two cycles for induction in a lifetime; and - up to three additional cycles for consolidation in a lifetime in patients who achieve a complete response after induction. Patients with Philadelphia chromosome positive disease must have previously received a tyrosine kinase inhibitor before receiving blinatumomab. Complete response is defined as a patient who: - has 5% or less bone marrow blasts; and - has no evidence of disease; and - has platelet count of more than 50,000 per microlitre; and - has absolute neutrophil count of more than 500 per microlitre. Patients must not have received blinatumomab previously for the treatment of MRD OR patients must have had a relapse-free period of at least six months following completion of treatment with blinatumomab for minimal residual disease.MAF96001200
BortezomibBortezomib injection (3.5mg)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)
Brentuximab vedotinBrentuximab vedotin powder for infusion (50 mg) AdcetrisBrentuximab in combination with cyclophosphamide, doxorubicin and prednisone (CHP), for previously untreated CD30+ peripheral T-cell lymphoma.MAF1800600
Brentuximab vedotinBrentuximab vedotin powder for infusion (50 mg) AdcetrisTreatment of relapsed or refractory systemic anaplastic large cell lymphoma. Treatment should be stopped at 16 cycles, or earlier if disease progresses.MAF1800600
Brentuximab vedotinBrentuximab vedotin powder for infusion (50 mg) AdcetrisTreatment of patients with CD30+ cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy. Treatment should be stopped at 16 cycles, or earlier if disease progresses.MAF1800600
Brentuximab vedotinBrentuximab vedotin powder for infusion (50 mg) AdcetrisTreatment of adults with previously untreated CD30+ advanced classic Hodgkin lymphoma (cHL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).No subsidy1800600
Brentuximab vedotinBrentuximab vedotin powder for infusion (50 mg) AdcetrisTreatment of adults with CD30+ Hodgkin lymphoma (HL) who are at increased risk of relapse or progression following an autologous stem cell transplant (ASCT). Treatment should be stopped at 16 cycles, or earlier if disease progresses.No subsidy1800600
Brentuximab vedotinBrentuximab vedotin powder for infusion (50 mg) AdcetrisTreatment of adults with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following autologous stem cell transplant (ASCT) or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. Treatment should be stopped at 16 cycles, or earlier if disease progresses.MAF1800600
BrigatinibBrigatinib tablet (30 mg, 90 mg, 180 mg)AlunbrigTreatment of locally advanced or metastatic ALK- positive non-small cell lung cancer.MAF2000600
BusulfanBusulfan tablet (2 mg)-For cancer treatment.SDL200600
CabazitaxelCabazitaxel injection (60 mg/1.5 mL)JevtanaCabazitaxel in combination with prednisolone: for the treatment of adult patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen.No subsidy1400600
CabozantinibCabozantinib tablet (20 mg, 40 mg, 60 mg)CabometyxFor previously treated advanced renal cell carcinoma.No subsidy1800600
CabozantinibCabozantinib tablet (20 mg, 40 mg, 60 mg)CabometyxTreatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.No subsidy1800600
CabozantinibCabozantinib tablet (20 mg, 40 mg, 60 mg)CabometyxFor untreated intermediate- or poor-risk advanced renal cell carcinoma.No subsidy1800600
CapecitabineCapecitabine tablet (150 mg, 500 mg)-For cancer treatment.SDL200600
CarboplatinCarboplatin vial (150 mg/15 mL, 450 mg/45 mL)-For cancer treatment.SDL200600
CarfilzomibCarfilzomib powder for solution for infusion (30 mg)KyprolisCarfilzomib in combination with lenalidomide or thalidomide or cyclophosphamide, plus dexamethasone, for patients with multiple myeloma who have received at least one prior therapy. Treatment with carfilzomib should be stopped after 18 cycles, or earlier if disease progresses.MAF2000600
CarfilzomibCarfilzomib powder for solution for infusion (30 mg)KyprolisCarfilzomib in combination with dexamethasone for patients with multiple myeloma who have received at least one prior therapy.MAF2000600
Carmustine Carmustine injection (100 mg)BiCNUFor cancer treatment.SDL2000600
CeritinibCeritinib capsule (150 mg)ZykadiaFor cancer treatment.SDL1000600
CetuximabCetuximab solution for infusion (100 mg/20 mL)ErbituxCetuximab in combination with platinum-based chemotherapy for patients with unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN).MAF1000600
CetuximabCetuximab solution for infusion (100 mg/20 mL)ErbituxCetuximab in combination with radiation therapy for patients with locally advanced squamous cell cancer of the head and neck (LASCCHN) who have contraindications or intolerance to platinum-based chemoradiation therapy.MAF1000600
CetuximabCetuximab solution for infusion (100 mg/20 mL)ErbituxCetuximab as monotherapy or in combination with chemotherapy, for treating RAS wild-type metastatic colorectal cancer.No subsidy1000600
Chlorambucil Chlorambucil tablet (2 mg)LeukeranFor cancer treatment.SDL400600
Cisplatin Cisplatin injection (50 mg/50 mL, 100 mg injection)-For cancer treatment.SDL200600
CrizotinibCrizotinib capsule (200 mg, 250 mg)XalkoriTreatment of patients with locally advanced or metastatic ROS1-positive NSCLC. Patients must not have received prior treatment with other ROS1 inhibitors.No subsidy3000600
CyclophosphamideCyclophosphamide vial (1 g) and tablet (50 mg)EndoxanFor cancer treatment.SDL200600
CyproteroneCyproterone tablet (50 mg)-For cancer treatment.SDL200600
CytarabineCytarabine vial (1 g/10 mL)-For cancer treatment.SDL400600
Dabrafenib plus trametinibDabrafenib capsule (50 mg, 75 mg) Trametinib tablet (0.5 mg, 2 mg)Tafinlar MekinistDabrafenib in combination with trametinib for treating locally advanced or metastatic anaplastic thyroid cancer in patients with a BRAF V600 mutation and with no satisfactory locoregional treatment options.MAF3800600
Dabrafenib plus trametinibDabrafenib capsule (50 mg, 75 mg) Trametinib tablet (0.5 mg, 2 mg)Tafinlar MekinistDabrafenib in combination with trametinib for the adjuvant treatment of completely resected malignant melanoma in patients with BRAF V600 mutation-positive disease and lymph node involvement. Maximum duration of treatment: 12 months.No subsidy3800600
Dabrafenib plus trametinibDabrafenib capsule (50 mg, 75 mg) Trametinib tablet (0.5 mg, 2 mg)Tafinlar MekinistDabrafenib in combination with trametinib for the treatment of advanced unresectable malignant melanoma in patients with a BRAF V600 mutation. Patients must not have received prior treatment with a BRAF/MEK inhibitor for metastatic melanoma.MAF3800600
Dabrafenib plus trametinibDabrafenib capsule (50 mg, 75 mg) Trametinib tablet (0.5 mg, 2 mg)Tafinlar MekinistDabrafenib in combination with trametinib for the treatment of advanced non-small cell lung cancer (NSCLC) in patients with a BRAF V600 mutation.MAF3800600
DacarbazineDacarbazine vial (200 mg)-For cancer treatment.SDL600600
DacomitinibDacomitinib tablet (15 mg, 30 mg, 45 mg)VizimproFor cancer treatment.SDL600600
Dactinomycin Dactinomycin vial (500 mcg)-For cancer treatment.SDL1400600
DaratumumabDaratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL)DarzalexDaratumumab in combination with bortezomib, thalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant.No subsidy2000600
DaratumumabDaratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL)DarzalexDaratumumab in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.No subsidy2000600
DaratumumabDaratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL)DarzalexDaratumumab in combination with bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.No subsidy2000600
DaratumumabDaratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL)DarzalexDaratumumab in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for an autologous stem cell transplant.No subsidy2000600
DarolutamideDarolutamide tablet (300 mg)NubeqaTreatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).No subsidy400600
DasatinibDasatinib tablet (20 mg, 50 mg, 70 mg)SprycelTreatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase.MAF1200600
DasatinibDasatinib tablet (20 mg, 50 mg, 70 mg)SprycelTreatment of adults with treatment-resistant or treatment-intolerant CML in chronic phase, accelerated phase, or myeloid or lymphoid blast phase or children with treatment-resistant or treatment-intolerant CML in chronic phase.MAF1200600
DasatinibDasatinib tablet (20 mg, 50 mg, 70 mg)SprycelTreatment of newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy. MAF1200600
DasatinibDasatinib tablet (20 mg, 50 mg, 70 mg)SprycelTreatment of adults with Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior treatment with imatinib.MAF1200600
Daunorubicin Daunorubicin vial (20 mg )-For cancer treatment.SDL400600
DegarelixDegarelix injection (80 mg, 120 mg)FirmagonTreatment of adults with advanced hormone-dependent prostate cancer.MAF200600
DexamethasoneDexamethasone injection (4 mg) and tablet (4 mg)-For cancer treatment.SDL200600
DocetaxelDocetaxel vial (20 mg , 80 mg, 160 mg)-For cancer treatment.SDL200600
DoxorubicinDoxorubicin vial (50 mg)-For cancer treatment.SDL200600
DurvalumabDurvalumab concentrate for solution for infusion (120 mg/2.4 mL, 500 mg/10 mL)ImfinziConsolidation treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemo-radiation therapy. Treatment should be continued until disease progression or unacceptable toxicity or a maximum of 12 months.MAF1800600
DurvalumabDurvalumab concentrate for solution for infusion (120 mg/2.4 mL, 500 mg/10 mL)ImfinziDurvalumab in combination with a platinum agent and etoposide, for previously untreated extensive-stage small cell lung cancer.MAF1800600
EntrectinibEntrectinib capsule (100 mg, 200 mg)RozlytrekTreatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. Patients must not have received prior treatment with other ROS1 inhibitors.No subsidy3000600
EntrectinibEntrectinib capsule (100 mg, 200 mg)RozlytrekTreatment of patients with solid tumours that: - have a NTRK gene fusion without a known acquired resistance mutation, - are metastatic or where surgical resection is likely to result in severe morbidity, and - have no satisfactory alternative treatments or that have progressed following treatment.No subsidy3000600
EnzalutamideEnzalutamide capsule (40 mg) XtandiTreatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).MAF400600
EnzalutamideEnzalutamide capsule (40 mg) XtandiTreatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC). MAF400600
EnzalutamideEnzalutamide capsule (40 mg) XtandiTreatment of adult men with metastatic castration-resistant prostate cancer (mCRPC).MAF400600
EpirubicinEpirubicin injection (50 mg)-For cancer treatment.SDL600600
ErdafitinibErdafitinib tablet (3 mg, 4 mg, 5 mg)BalversaTreatment of patients with locally advanced or metastatic urothelial carcinoma, whose tumours have susceptible FGFR3 genetic alterations, and who have disease progression during or following at least one line of prior chemotherapy including within 12 months of neoadjuvant or adjuvant chemotherapy.No subsidy1800600
EribulinEribulin mesylate solution for injection (1 mg/2 mL)HalavenTreatment of locally advanced or metastatic breast cancer in patients whose disease has progressed after >= 2 chemotherapy regimens for advanced disease.MAF1200600
EribulinEribulin mesylate solution for injection (1 mg/2 mL)HalavenTreatment of adults with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.MAF1200600
ErlotinibErlotinib tablet (25 mg, 100 mg, 150 mg)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)
EtoposideEtoposide capsule (50 mg)-For cancer treatment.SDL600600
EtoposideEtoposide vial (100 mg/5 mL)-For cancer treatment.SDL200600
EverolimusEverolimus tablet (2.5 mg, 5 mg, 10 mg)AfinitorEverolimus in combination with exemestine for HR positive, HER2/neu negative advanced breast cancer, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.No subsidy1200600
EverolimusEverolimus tablet (2.5 mg, 5 mg, 10 mg)AfinitorFor previously treated advanced renal cell carcinoma.No subsidy1200600
EverolimusEverolimus tablet (2.5 mg, 5 mg, 10 mg)AfinitorTreatment of unresectable, locally advanced or metastatic neuroendocrine tumours of pancreatic origin and with progressive disease.MAF1200600
EverolimusEverolimus tablet (2.5 mg, 5 mg, 10 mg)AfinitorTreatment of unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours of gastrointestinal or lung origin and with progressive disease.MAF1200600
ExemestaneExemestane tablet (25 mg)-For cancer treatment.SDL200600
FludarabineFludarabine injection (50 mg)-For cancer treatment.SDL600600
FluorouracilFluorouracil vial (500 mg/10 mL, 1g/20 mL, 5g/100 mL)-For cancer treatment.SDL200600
Fluorouracil (5-fluorouracil) cream5-fluorouracil cream (5%)-Treatment of actinic keratosis, Bowen’s disease, or superficial basal cell carcinoma.No subsidy200600
Folinic acidFolinic acid vial (50 mg/5 mL, 300 mg/30 mL)-For cancer treatment.SDL200600
FulvestrantFulvestrant solution for injection in pre-filled syringe (250 mg/5 mL)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)
GefitinibGefitinib tablet (250 mg)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)
GemcitabineGemcitabine vial (200 mg, 1 g, 2 g)-For cancer treatment.SDL200600
Gilteritinib Gilteritinib tablet (40 mg)XospataTreatment of FLT-3 mutation positive relapsed / refractory acute myeloid leukaemia (AML). Gilteritinib is not recommended as maintenance therapy for patients after HSCT.  (Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)
GoserelinGoserelin acetate depot syringe (3.6 mg, 10.8 mg)ZoladexTreatment of breast cancer in pre- and perimenopausal women in which hormone therapy is specified.MAF200600
GoserelinGoserelin acetate depot syringe (3.6 mg, 10.8 mg)Zoladex1) As primary therapy for men with locally advanced or metastatic prostate cancer 2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy 3) For men with prostate cancer who have a biochemical relapse. LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancerMAF200600
Hydroxyurea Hydroxyurea capsule (500 mg)-For cancer treatment.SDL200600
IbrutinibIbrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 420 mg)
ImbruvicaMonotherapy for patients with previously untreated untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are unsuitable for fludarabine-based therapy.No subsidy2000600
IbrutinibIbrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 420 mg)
ImbruvicaIbrutinib in combination with rituximab biosimilar or obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).No subsidy2000600
Ibrutinib Ibrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 420 mg) ImbruvicaMonotherapy for patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy.No subsidy2000600
IbrutinibIbrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 560 mg)ImbruvicaTreatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy.No subsidy2000600
IbrutinibIbrutinib capsule (140 mg) and tablet (140 mg, 280 mg, 420 mg)ImbruvicaIbrutinib as a single agent, or in combination with rituximab biosimilar, for the treatment of Waldenstrom’s Macroglobulinaemia.No subsidy2000600
Idarubicin Idarubicin solution for injection (5 mg/5 mL and 10 mg/10 mL)Zavedos CSTreatment of acute myeloid leukaemia (AML) in adults for remission induction.No subsidy400600
IfosfamideIfosfamide infusion (1 g)HoloxanFor cancer treatment.SDL2400600
ImatinibImatinib tablet (100 mg, 400 mg)-For cancer treatment.SDL (Generic)(Undergoing Evaluation)(Undergoing Evaluation)
Imiquimod creamImiquimod cream (5%) AldaraTreatment of actinic keratosis or superficial basal cell carcinoma.No subsidy200600
Inotuzumab ozogamicinInotuzumab ozogamicin powder for concentrate for solution for infusion (1 mg per vial) BesponsaTreatment of adults with relapsed or refractory CD22 positive B-cell precursor acute lymphoblastic leukemia (ALL) for: - up to a maximum of three cycles for induction in a lifetime, and - up to three additional cycles for consolidation in a lifetime in patients who achieve a complete response after induction Patients with Philadelphia chromosome positive disease must have previously received a tyrosine kinase inhibitor before receiving inotuzumab. Complete response is defined as a patient who: a) has 5% or less bone marrow blasts; and b) has no evidence of disease; and c) has platelet count of more than 50,000 per microlitre; and d) has absolute neutrophil count of more than 500 per microlitre.MAF96001200
Interferon alfa 2aInterferon alfa 2a injection (3 million iu/ 0.5 mL)-For cancer treatment.SDL400600
Ipilimumab plus nivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Ipilimumab injection concentrate (50 mg/10 mL)Opdivo YervoyFor untreated intermediate- or poor-risk advanced renal cell carcinoma. The doses of nivolumab and ipilimumab should not exceed: 3mg/kg nivolumab and 1mg/kg ipilimumab every 3 weeks for 4 doses. Re-induction with ipilimumab is not allowed.MAF5200600
IrinotecanIrinotecan vial (100 mg/5 mL)-For cancer treatment.SDL200600
IxazomibIxazomib capsule (3 mg, 4 mg)NinlaroIxazomib in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.MAF2000600
LanreotideLanreotide prolonged release (PR) injection (60 mg, 90 mg, 120 mg)Somatuline AutogelTreatment of neuroendocrine tumours of gastrointestinal or pancreatic origin.No subsidy600600
LanreotideLanreotide prolonged release (PR) injection (60 mg, 90 mg, 120 mg)Somatuline AutogelFor the reduction of symptoms associated with carcinoid syndrome.No subsidy600600
LapatinibLapatinib tablet (250 mg)TykerbLapatinib in combination with an aromatase inhibitor for postmenopausal women with HR positive, HER2 positive metastatic breast cancer.MAF600600
LapatinibLapatinib tablet (250 mg)TykerbLapatinib in combination with capecitabine for HER2 positive, advanced or metastatic breast cancer in patients whose disease has progressed after treatment with an anthracycline and, a taxane, and on prior trastuzumab therapy in the metastatic setting.MAF600600
LarotrectinibLarotrectinib capsule (25 mg, 100 mg) and oral solution (2 g/100 mL)VitrakviTreatment of patients with solid tumours that: - have a NTRK gene fusion without a known acquired resistance mutation, - are metastatic or where surgical resection is likely to result in severe morbidity, and - have no satisfactory alternative treatments or that have progressed following treatment.No subsidy3000600
L-asparaginaseL-asparaginase injection (10,000 IU)LeunaseFor cancer treatment.SDL1000600
LenalidomideLenalidomide capsule (5 mg, 10 mg, 15 mg, 25 mg)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)
LenvatinibLenvatinib capsule (4 mg, 10 mg)LenvimaTreatment of advanced unresectable hepatocellular carcinoma in patients with adequate liver function as assessed by the Child-Pugh scoring system, when used according to HSA-recommended dosing regimens.MAF1200600
LenvatinibLenvatinib capsule (4 mg, 10 mg)LenvimaTreatment of locally advanced or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.MAF1200600
LenvatinibLenvatinib capsule (4 mg, 10 mg)LenvimaLenvatinib in combination with everolimus for previously treated advanced renal cell carcinoma.No subsidy1200600
LetrozoleLetrozole tablet (2.5 mg)-For cancer treatment.SDL200600
LeuprorelinLeuprorelin acetate for depot suspension (3.75 mg) (Lucrin)LucrinTreatment of breast cancer in pre- and perimenopausal women in which hormone therapy is specified.MAF200600
LeuprorelinLeuprorelin acetate injection (3.75 mg, 5 mg/ml, 7.5 mg, 11.25 mg, 22.5 mg, 30 mg, 45 mg) Lucrin Eligard1) As primary therapy for men with locally advanced or metastatic prostate cancer 2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy 3) For men with prostate cancer who have a biochemical relapse. LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancerMAF200600
Liposomal doxorubicinLiposomal doxorubicin concentrate for infusion (20 mg, 50 mg) (Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)
Liposomal irinotecanPegylated liposomal irinotecan concentrate for dispersion for infusion (43 mg/ 10 mL)OnivydeLiposomal irinotecan in combination with fluorouracil and leucovorin, for patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.No subsidy200600
Lomustine Lomustine capsule (40 mg)-For cancer treatment.SDL200600
LorlatinibLorlatinib tablet (25 mg, 100 mg)LorviquaTreatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer whose disease has progressed after an ALK inhibitor other than crizotinib.No subsidy2000600
Lutetium oxodotreotideLutetium-177 (177-Lu) peptide-Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor-positive gastro-entero-pancreatic neuroendocrine tumours (NETs), including foregut, midgut, and hindgut NETs in adults.No subsidy1200600
Lutetium PSMA Lutetium PSMA -Treatment of adults with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen.No subsidy1400600
MegestrolMegestrol capsule (40 mg, 160 mg)-For cancer treatment.SDL200600
MelphalanMelphalan injection (50 mg)AlkeranFor cancer treatment.SDL400600
MelphalanMelphalan tablet (2 mg)AlkeranFor cancer treatment.SDL200600
MercaptopurineMercaptopurine tablet (50 mg)-For cancer treatment.SDL200600
Meta-iodobenzylguanidine [I-131]Meta-iodobenzylguanidine [I-131] injection for therapeutic use (185 to 740 MBq/mL)-Radiation therapy of tumours arising from cells originating embryologically from the neural crest, pheochromocytomas, neuroblastomas, carcinoids and medullary carcinomas of the thyroid gland.No subsidy3000600
MethotrexateMethotrexate vial (50 mg/2 mL, 1g/10 mL) -For cancer treatment.SDL400600
MethotrexateMethotrexate tablet (2.5 mg)-For cancer treatment.SDL200600
MethylprednisoloneMethylprednisolone vial (62.5mg/mL)-For cancer treatment.SDL200600
Midostaurin Midostaurin tablet (25 mg) RydaptTreatment of FLT-3-mutation positive acute myeloid leukaemia (AML) in combination with standard intensive induction and consolidation chemotherapy. Standard induction chemotherapy must include cytarabine and an anthracycline. Midostaurin is not recommended for maintenance therapy.MAF2400600
MitomycinMitomycin injection (2 mg, 10 mg)-For cancer treatment.SDL200600
MitoxantroneMitoxantrone vial (20 mg/10 mL)-For cancer treatment.SDL1000600
Nab-paclitaxelPaclitaxel - albumin bound nanoparticles injectable suspension (100 mg)AbraxaneMonotherapy for breast cancer in adults who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.MAF1000600
Nab-paclitaxelPaclitaxel - albumin bound nanoparticles injectable suspension (100 mg)AbraxaneNab-paclitaxel in combination with gemcitabine, for previously untreated metastatic adenocarcinoma of the pancreas.MAF1000600
Nab-paclitaxelPaclitaxel - albumin bound nanoparticles injectable suspension (100 mg)AbraxaneNab-paclitaxel in combination with carboplatin, for previously untreated locally advanced or metastatic non-small cell lung cancer in patients who are not candidates for curative surgery or radiation therapy.MAF1000600
NilotinibNilotinib capsule (50 mg, 150 mg, 200 mg)TasignaTreatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase.MAF1200600
NilotinibNilotinib capsule (50 mg, 150 mg, 200 mg)TasignaTreatment of adults with treatment-resistant or treatment-intolerant chronic myeloid leukaemia (CML) in chronic phase or accelerated phase; or children with treatment-resistant or treatment-intolerant CML in chronic phase.MAF1200600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoTreatment of patients with unresectable locally advanced or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma after 2 or more prior systemic therapies. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for gastric or GEJ cancer. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. MAF1800600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoTreatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for MSI-H or dMMR CRC. The dose of nivolumab should not exceed 240mg every 2 weeks or 480mg every 4 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoNivolumab in combination with ipilimumab for treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for MSI-H or dMMR CRC. The doses of nivolumab and ipilimumab should not exceed: 3mg/kg nivolumab and 1mg/kg ipilimumab every 3 weeks for 4 doses, followed by nivolumab 240mg every 2 weeks or 480mg every 4 weeks as a single agent. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. Re-induction with ipilimumab is not allowed.No subsidy1800600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoTreatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. MAF1800600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoTreatment of patients with locally advanced or metastatic urothelial carcinoma (UC) after receiving platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for UC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoTreatment of advanced unresectable hepatocellular carcinoma (HCC) in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for HCC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoNivolumab in combination with ipilimumab for treatment of advanced unresectable hepatocellular carcinoma (HCC) in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for HCC. The doses of nivolumab and ipilimumab should not exceed: 1mg/kg nivolumab and 3mg/kg ipilimumab every 3 weeks for 4 doses, followed by nivolumab 240mg every 2 weeks or 480mg every 4 weeks as a single agent. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. Re-induction with ipilimumab is not allowed.No subsidy1800600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoNivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy, for previously untreated metastatic or recurrent non-small cell lung cancer (NSCLC) in patients with no EGFR or ALK genomic tumour mutations. The doses of nivolumab and ipilimumab should not exceed: 360mg nivolumab every 3 weeks and 1mg/kg ipilimumab every 6 weeks. Treatment with nivolumab and ipilimumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoFor previously treated advanced renal cell carcinoma (RCC). Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for RCC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.MAF1800600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoAdjuvant treatment of completely resected malignant melanoma in patients with lymph node involvement. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Maximum duration of treatment: 12 months.MAF1800600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoMonotherapy for advanced unresectable malignant melanoma. Patients must not have received prior treatment with a PD-1 inhibitor or ipilimumab for metastatic melanoma. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.MAF1800600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoFor untreated intermediate- or poor-risk advanced renal cell carcinoma, following induction treatment with nivolumab in combination with ipilimumab. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. MAF1800600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoNivolumab in combination with ipilimumab for the treatment of advanced unresectable malignant melanoma. Patients must not have received prior treatment with a PD-1 inhibitor or ipilimumab for metastatic melanoma. The doses of nivolumab and ipilimumab should not exceed: 1mg/kg nivolumab and 3mg/kg ipilimumab every 3 weeks for 4 doses, followed by 3 mg/kg nivolumab every 2 weeks as a single agent. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. Re-induction with ipilimumab is not allowed.No subsidy1800600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoFor patients with unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN) whose disease progressed within six months of starting platinum-based chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for RMSCCHN. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. MAF1800600
NivolumabNivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)OpdivoTreatment of adults with relapsed or refractory classical Hodgkin lymphoma (cHL) after an autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for relapsed or refractory cHL. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if the person has an allogeneic stem cell transplant or the disease progresses. MAF1800600
ObinutuzumabObinutuzumab concentrate for solution for infusion (1000 mg/40 mL)GazyvaObinutuzumab in combination with chemotherapy, for previously untreated stage II bulky, III or IV follicular lymphoma. Patients achieving at least a partial remission may continue to receive maintenance treatment with obinutuzumab monotherapy. Maintenance treatment with obinutuzumab should be stopped after 2 years, or earlier if disease progresses.No subsidy1800600
ObinutuzumabObinutuzumab concentrate for solution for infusion (1000 mg/40 mL)GazyvaObinutuzumab in combination with bendamustine, for the treatment of follicular lymphoma that has not responded to or progressed within 6 months after treatment with rituximab or a rituximab-containing regimen. Patients must not have received obinutuzumab for follicular lymphoma. Maintenance treatment with obinutuzumab should be stopped at 2 years, or earlier if disease progresses.MAF1800600
OctreotideOctreotide long-acting depot injection (20 mg, 30 mg)Sandostatin LARFor cancer treatment.SDL600600
OlaparibOlaparib tablet (100 mg, 150 mg)LynparzaMaintenance treatment of patients with deleterious or suspected deleterious germline BRCA mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.MAF1600600
OlaparibOlaparib tablet (100 mg, 150 mg)LynparzaTreatment of germline BRCA-mutated, HER2 negative, locally advanced or metastatic breast cancer in patients previously treated with chemotherapy.MAF1600600
OlaparibOlaparib tablet (100 mg, 150 mg)LynparzaTreatment of adults with metastatic castration-resistant prostate cancer and homologous recombination repair gene BRCA1/2 and/or ATM-mutations (germline and/or somatic) who have progressed following a prior treatment with abiraterone or second generation anti-androgen.MAF1600600
OlaparibOlaparib tablet (100 mg, 150 mg)LynparzaMaintenance monotherapy for adults with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Treatment should be continued until disease progression or unacceptable toxicity or a maximum of 24 months.MAF1600600
OlaparibOlaparib tablet (100 mg, 150 mg)LynparzaOlaparib in combination with bevacizumab as maintenance treatment of adults with advanced homologous recombination deficiency (HRD) positive high grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab. Treatment with olaparib should be continued until disease progression or unacceptable toxicity or a maximum of 24 months.MAF1600600
OlaparibOlaparib tablet (100 mg, 150 mg)LynparzaMaintenance monotherapy for adults with platinum-sensitive relapsed BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Patients must not have received prior treatment with a PARP inhibitor for ovarian cancer. Treatment should be continued until disease progression or unacceptable toxicity. MAF1600600
OsimertinibOsimertinib tablet (40 mg, 80 mg)TagrissoFor previously untreated locally advanced or metastatic EGFR mutation positive non-small cell lung cancer.No subsidy600600
OsimertinibOsimertinib tablet (40 mg, 80 mg)TagrissoTreatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR TKI therapy.MAF600600
OsimertinibOsimertinib tablet (40 mg, 80 mg)TagrissoAdjuvant treatment after tumour resection in patients with stage IB to IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. Treatment should be continued until disease recurrence or unacceptable toxicity or a maximum of 3 years.No subsidy600600
Oxaliplatin Oxaliplatin injection (50 mg, 100 mg, 200 mg)-For cancer treatment.SDL200600
PaclitaxelPaclitaxel vial (150 mg/25 mL, 300 mg/50 mL)-For cancer treatment.SDL200600
PalbociclibPalbociclib capsule (75 mg, 100 mg, 125 mg)IbrancePalbociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer.MAF800600
PalbociclibPalbociclib capsule (75 mg, 100 mg, 125 mg)IbrancePalbociclib in combination with fulvestrant for treating HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy.MAF800600
PanitumumabPanitumumab concentrate for solution for infusion (100 mg/5 mL)VectibixFor cancer treatment.SDL1000600
PazopanibPazopanib tablet (200 mg, 400 mg)VotrientFor cancer treatment.SDL1600600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaAdjuvant treatment of completely resected malignant melanoma in patients with lymph node involvement. Maximum duration of treatment: 12 months.MAF1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaTreatment of advanced unresectable malignant melanoma. Patients must not have received a PD-1 inhibitor or ipilimumab for metastatic melanoma. Treatment with PD-1 inhibitor should be stopped at 2 years, or earlier if disease progresses.MAF1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaTreatment of metastatic Merkel cell carcinoma.MAF1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaPembrolizumab in combination with axitinib for untreated advanced renal cell carcinoma. Treatment with PD-1/PD-L1 inhibitor should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaMonotherapy for previously untreated unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN) with PD-L1 CPS≥1. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. MAF1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaPembrolizumab in combination with platinum-based chemotherapy, for previously untreated unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN) with PD-L1 CPS≥1. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.MAF1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaPembrolizumab in combination with lenvatinib for treating advanced endometrial carcinoma that is not microsatellite instability-high (non-MSI-H) or mismatch repair deficient (non-dMMR), who have disease progression following prior chemotherapy in the metastatic setting and are not candidates for curative surgery or radiation.No subsidy1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaFor previously untreated metastatic non-small cell lung cancer (NSCLC) in patients whose tumours express PD-L1 with a tumour proportion score ≥50%, with no EGFR or ALK genomic tumour aberrations.Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.MAF1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaTreatment of patients with metastatic non-small cell lung cancer (NSCLC), whose tumours express PD-L1 with a tumour proportion score ≥1% and had disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.MAF1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaPembrolizumab in combination with carboplatin and nab- paclitaxel for previously untreated metastatic squamous non-small cell lung cancer (NSCLC). Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaPembrolizumab in combination with carboplatin and paclitaxel for previously untreated metastatic squamous non-small cell lung cancer (NSCLC). Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.MAF1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaPembrolizumab in combination with pemetrexed and platinum chemotherapy, for previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC) in patients with no EGFR or ALK genomic tumour aberrations. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.MAF1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaTreatment of advanced unresectable hepatocellular carcinoma (HCC) in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for HCC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaTreatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and who have no satisfactory alternative treatment options. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for a MSI-H or dMMR solid tumour. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaTreatment of patients with locally advanced or metastatic urothelial carcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥10, and who are not eligible for cisplatin-containing chemotherapy. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaTreatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses.No subsidy1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaTreatment of patients with locally advanced or metastatic urothelial carcinoma (UC) after receiving platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for UC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. MAF1800600
PembrolizumabPembrolizumab solution for infusion (100 mg/4 mL)KeytrudaTreatment of patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for relapsed or refractory cHL. Treatment with pembrolizumab should be stopped at 2 years, or earlier if the person has a stem cell transplant or the disease progresses.MAF1800600
PemetrexedPemetrexed injection (100 mg, 500 mg)-For cancer treatment.SDL200600
PertuzumabPertuzumab concentrate for solution for infusion (420 mg/14 mL)PerjetaPertuzumab in combination with trastuzumab biosimilar and chemotherapy for neoadjuvant treatment of HER2 positive locally advanced, inflammatory or early stage (tumour >2 cm in diameter or node positive) breast cancer for 4 to 6 cycles. Following surgery, patients may continue with trastuzumab with or without pertuzumab for a total of 1 year of anti-HER2 treatment. No subsidy1600600
PertuzumabPertuzumab concentrate for solution for infusion (420 mg/14 mL)PerjetaPertuzumab in combination with trastuzumab biosimilar and chemotherapy for adjuvant treatment of high-risk (with positive nodes) HER2 positive early breast cancer for a maximum duration of 1 year. No subsidy1600600
PertuzumabPertuzumab concentrate for solution for infusion (420 mg/14 mL)PerjetaPertuzumab in combination with trastuzumab biosimilar and a taxane for HER2 positive metastatic or locally recurrent breast cancer, in patients without prior treatment for metastatic disease. Treatment with pertuzumab should be stopped if disease progresses. No subsidy1600600
PomalidomidePomalidomide capsule (1 mg, 2 mg, 3 mg, 4 mg)PomalystPomalidomide in combination with bortezomib or cyclophosphamide, plus dexamethasone, for patients with multiple myeloma who have received at least one prior therapy. MAF2000600
PomalidomidePomalidomide capsule (1 mg, 2 mg, 3 mg, 4 mg)PomalystPomalidomide in combination with dexamethasone for patients with multiple myeloma who have received at least two prior therapies, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.MAF2000600
PonatinibPonatinib tablet (15 mg)IclusigTreatment of chronic, accelerated, or blast phase chronic myeloid leukaemia (CML) in adults: • whose disease is resistant to imatinib or dasatinib or nilotinib, and who have the T315I mutation OR • whose disease is resistant to both nilotinib and dasatinib OR • whose disease is resistant to nilotinib or dasatinib and who are intolerant of/contraindicated to the other drug.MAF1200600
PonatinibPonatinib tablet (15 mg)IclusigTreatment of adults with Philadelphia chromosome positive acute lymphoblastic leukaemia who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.MAF1200600
PrednisolonePrednisolone tablet (1 mg, 5 mg, 20 mg)-For cancer treatment.SDL200600
Procarbazine Procarbazine capsule (50 mg)-For cancer treatment.SDL800600
Radium-223 Radium-223 solution for injection (1100 kBq/mL)XofigoTreatment of patients with castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.No subsidy1400600
RamucirumabRamucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL)CyramzaTreatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have serum alpha-fetoprotein (AFP) of ≥400 ng/ml, and have adequate liver function as assessed by the Child-Pugh scoring system.No subsidy1800600
RamucirumabRamucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL)CyramzaRamucirumab as monotherapy for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.No subsidy1800600
RamucirumabRamucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL)CyramzaRamucirumab in combination with paclitaxel for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.No subsidy1800600
RamucirumabRamucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL)CyramzaRamucirumab in combination with FOLFIRI for treating metastatic colorectal cancer that has progressed on first-line systemic therapy.No subsidy1800600
RegorafenibRegorafenib tablet (40 mg)StivargaTreatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumour (GIST) who have been previously treated with imatinib mesylate.MAF1800600
RegorafenibRegorafenib tablet (40 mg)StivargaTreatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.MAF1800600
RegorafenibRegorafenib tablet (40 mg)StivargaTreatment of metastatic colorectal cancer that has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy.MAF1800600
RibociclibRibociclib tablet (200 mg)KisqaliRibociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer.MAF800600
RibociclibRibociclib tablet (200 mg)KisqaliRibociclib in combination with fulvestrant for HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy.MAF800600
RituximabRituximab biosimilar concentrate for infusion (100 mg/10 mL, 500 mg/50 mL)TruximaFor cancer treatment.SDL1000600
RituximabRituximab concentrate for infusion (100 mg/10 mL, 500 mg/50 mL)Mabthera RixathonFor cancer treatment.No subsidy1000600
RituximabRituximab solution for subcutaneous injection (1400 mg/1.7 mL)MabtheraRituximab (subcutaneous) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), for the treatment of CD20+ diffuse large B-cell non-Hodgkin lymphoma.No subsidy1000600
RituximabRituximab solution for subcutaneous injection (1400 mg)MabtheraRituximab (subcutaneous) in combination with cyclophosphamide, vincristine, prednisone (CVP), for the treatment of previously untreated patients with stage III-IV follicular lymphoma. No subsidy1000600
RituximabRituximab solution for subcutaneous injection (1400 mg)MabtheraRituximab (subcutaneous) for maintenance treatment of patients with follicular lymphoma who have responded to induction therapy.No subsidy1000600
RomidepsinRomidepsin powder for solution for infusion (10 mg)-Treatment of peripheral T-cell lymphoma in adults who have received at least one prior therapy.No subsidy1800600
RuxolitinibRuxolitinib tablet (5 mg, 15 mg, 20 mg)Jakavi Treatment of patients with intermediate-2 or high-risk myelofibrosis with disease-related splenomegaly or symptoms.MAF2000600
SiltuximabSiltuximab powder for infusion (100 mg) SylvantTreatment of adults with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.No subsidy3000600
Sodium iodide [I-131]Sodium iodide [I-131] capsule (37 to 6000 MBq)-For thyroid residue ablation after surgery of differentiated thyroid cancer, and treatment of iodine-accumulating metastases.No subsidy1600600
SorafenibSorafenib tablet (200 mg)NexavarFor cancer treatment.SDL1200600
SunitinibSunitinib capsule (12.5 mg, 25 mg, 37.5 mg, 50 mg)SutentTreatment of patients with unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) who have had an inadequate response to imatinib mesylate treatment due to resistance or intolerance.No subsidy1600600
SunitinibSunitinib capsule (12.5 mg, 25 mg, 37.5 mg, 50 mg)SutentTreatment of advanced renal cell carcinoma.No subsidy1600600
SunitinibSunitinib capsule (12.5 mg, 25 mg, 37.5 mg, 50 mg)SutentTreatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease progression. No subsidy1600600
TalazoparibTalazoparib capsule (0.25 mg, 1 mg)TalzennaTreatment of germline BRCA-mutated, HER2 negative, locally advanced or metastatic breast cancer in patients previously treated with chemotherapy.No subsidy1600600
Tamoxifen Tamoxifen tablet (20 mg)-For cancer treatment.SDL200600
Tegafur+ gimeracil+ oteracil Tegafur+ gimeracil+ oteracil potassium capsule (20 mg/5.8 mg/19.6 mg, 25 mg/7.25 mg/24.5 mg)TS-ONETreatment of locally advanced or metastatic adenocarcinoma of the pancreas.No subsidy200600
Tegafur+ gimeracil+ oteracil Tegafur+ gimeracil+ oteracil potassium capsule (20 mg/5.8 mg/19.6 mg, 25 mg/7.25 mg/24.5 mg)TS-ONEPost-operative adjuvant treatment of locally advanced (stage II (excluding T1), IIIA or IIIB) gastric cancer.No subsidy200600
TemozolomideTemozolomide capsule (20 mg, 100 mg) -For cancer treatment.SDL800600
Thalidomide Thalidomide capsule (50 mg)-For cancer treatment.SDL400600
Tioguanine Tioguanine tablet (40 mg)-For cancer treatment.SDL1600600
TrabectedinTrabectedin powder for injection (1 mg) YondelisTreatment of patients with advanced or metastatic soft tissue sarcoma, after failure of anthracyclines and ifosfamide (unless unsuitable).No subsidy1200600
TrastuzumabTrastuzumab biosimilar powder for IV infusion (440 mg)OgivriFor cancer treatment.SDL600600
TrastuzumabTrastuzumab powder for IV infusion (440 mg)Herceptin Herzuma Kanjiti TrazimeraFor cancer treatment.No subsidy600600
TrastuzumabTrastuzumab solution for SC injection (600 mg/5 mL)HerceptinFor cancer treatment.No subsidy600600
Trastuzumab emtansineTrastuzumab emtansine powder for concentrate for infusion solution (100 mg, 160 mg)KadcylaAdjuvant treatment of HER2 positive early breast cancer in patients with residual invasive disease, after neoadjuvant treatment with trastuzumab and a taxane. Maximum 14 cycles.No subsidy1600600
Trastuzumab emtansineTrastuzumab emtansine powder for concentrate for infusion solution (100 mg, 160 mg)KadcylaTreatment of HER2 positive, locally advanced, unresectable, or metastatic breast cancer in patients who have received prior treatment with trastuzumab and a taxane.No subsidy1600600
TretinoinTretinoin capsule (10 mg)VesanoidFor cancer treatment.SDL800600
Trifluridine + tipiracil Trifluridine + tipiracil tablet (15 mg/6.14 mg, 20 mg/8.19 mg)LonsurfTreatment of metastatic colorectal cancer that has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy.No subsidy1800600
Trifluridine + tipiracil Trifluridine + tipiracil tablet (15 mg/6.14 mg, 20 mg/8.19 mg)LonsurfTreatment of patients with unresectable locally advanced or recurrent gastric or gastroesophageal junction adenocarcinoma after 2 or more prior systemic therapies.No subsidy1800600
TriptorelinTriptorelin injection (3.75 mg, 11.25 mg, 22.5 mg) -Treatment of locally advanced or metastatic, hormone-dependent prostate cancer.No subsidy200600
VenetoclaxVenetoclax tablet (10 mg, 50 mg, 100 mg)VenclextaMonotherapy after completion of 6 cycles of obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia (CLL) who are unsuitable for fludarabine-based therapy. MAF3000600
VenetoclaxVenetoclax tablet (10 mg, 50 mg, 100 mg)VenclextaVenetoclax in combination with rituximab biosimilar for patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. Maximum treatment duration of rituximab is 6 cycles and venetoclax is 24 months.MAF3000600
VenetoclaxVenetoclax tablet (10 mg, 50 mg, 100 mg)VenclextaTreatment of newly diagnosed acute myeloid leukaemia (AML) in combination with a hypomethylating agent or low-dose cytarabine in patients who are ineligible for intensive chemotherapy. No subsidy3000600
Venetoclax plus obinutuzumabVenetoclax tablet (10 mg, 50 mg, 100 mg)
Obinutuzumab concentrate for solution for infusion (1000 mg/40 mL)
Venclexta GazyvaVenetoclax in combination with obinutuzumab for patients with previously untreated chronic lymphocytic leukemia (CLL) who are unsuitable for fludarabine-based therapy. Maximum treatment duration of obinutuzumab is 6 cycles and venetoclax is 12 months. MAF5400600
Vinblastine sulfateVinblastine sulfate vial (10 mg)-For cancer treatment.SDL200600
Vincristine sulfate Vincristine sulfate vial (1 mg)-For cancer treatment.SDL200600
VinflunineVinflunine concentrate for solution for infusion (50 mg/2 mL, 100 mg/4 mL, 250 mg/10 mL)JavlorTreatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy.No subsidy1800600
VinorelbineVinorelbine capsule (20 mg, 30 mg)-(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)(Undergoing Evaluation)
VinorelbineVinorelbine injection (50 mg)-For cancer treatment.SDL400600